Treatment of Crohn’s disease with anti-IL-6 receptor antibody

Journal of Gastroenterology

Volumn 40, Issue , 2005, Pages 32-34

  Ito, Hiroaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

antibody; Crohn s disease; IL 6; IL 6 receptor; therapy

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; HUMAN; IMMUNOLOGY; MOUSE; MOUSE MUTANT; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ANIMALS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; HUMANS; MICE; MICE, SCID; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION;

EID: 21844437381     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/BF02990576     Document Type: Article

References (7)

1. Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36: 45–9. DOI: 10.1136/gut.36.1.45
2. Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14: 987–96. DOI: 10.1046/j.1440-1746.1999.01989.x
3. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001;193: 471–81. DOI: 10.1084/jem.193.4.471
4. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000;164: 4878–82.
5. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583–8. DOI: 10.1038/75068
6. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851–6.
7. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004; 126: 989–96. DOI: 10.1053/j.gastro.2004.01.012